Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations
Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of Rapamycin in extended cervicofacial lymphatic malformations in
pediatric patients. Rapamycin is administered oral for a 6 month period.
The success rate is determined by volume reduction superior to 1/5e of the initial volume
measured by MRI, impact on QOL and reduction of bleeding in case of mucosal involvement.